ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

TTHI Transition Therapeutics - Ordinary Shares

1.5248
0.00 (0.00%)
Last Updated: 20:00:00
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 0.0001
Ask Price 1.61
News -
Company Name Stock Ticker Symbol Market Type
Transition Therapeutics - Ordinary Shares TTHI NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 1.5248 20:00:00
Open Price Low Price High Price Close Price Prev Close
1.5248
Trades Volume Avg Volume
0 0 -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 1.5248 USD

Transition Therapeutics - Ordinary Shares Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 59.16M - - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Transition Therapeutics - Ordinary Shares News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No TTHI Message Board. Create One! See More Posts on TTHI Message Board See More Message Board Posts

Historical TTHI Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

Transition Therapeutics - Ordinary Shares Description

Transition Therapeutics Inc was incorporated on July 6, 1998 as 'Transition Therapeutics and Diagnostics Inc.' The Corporation filed articles of amendment on October 12, 2000 and on October 19, 2000 to create a class of non-voting shares (the 'Class B Shares') and to amend certain attributes of its Common Shares. On November 2, 2000, the Corporation filed articles of amendment to delete its private company restrictions. On December 14, 2000, the Corporation filed articles of amendment to change its name to 'Transition Therapeutics Inc.' The Company's technologies are focused on the treatment of Alzheimer's disease and diabetes. The Corporation operates in one business segment; that is the research and development of therapeutic agents. Its technologies in development include ELND005 (AZD-103) for the treatment of Alzheimer's disease.

Your Recent History

Delayed Upgrade Clock